Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors.

PubWeight™: 1.36‹?› | Rank: Top 10%

🔗 View Article (PMC 17893)

Published in Proc Natl Acad Sci U S A on August 31, 1999

Authors

Y Shoshan1, A Nishiyama, A Chang, S Mörk, G H Barnett, J K Cowell, B D Trapp, S M Staugaitis

Author Affiliations

1: Department of Neurosciences, The Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

Articles citing this

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev (2001) 4.53

Non-stem cell origin for oligodendroglioma. Cancer Cell (2010) 1.95

Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia (2007) 1.62

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol (2008) 1.45

The pathobiology of glioma tumors. Annu Rev Pathol (2010) 1.40

Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS? J Anat (2004) 1.39

The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene (2008) 1.38

Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse. Dev Biol (2010) 1.34

The interface between glial progenitors and gliomas. Acta Neuropathol (2008) 1.33

Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A (2001) 1.29

Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia (2011) 1.28

MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci (2011) 1.28

Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS One (2008) 1.20

A role for the NG2 proteoglycan in glioma progression. Cell Adh Migr (2008) 1.20

Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One (2011) 1.05

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol (2011) 1.03

The cellular origin for malignant glioma and prospects for clinical advancements. Expert Rev Mol Diagn (2012) 1.02

Glioblastoma-initiating cells: relationship with neural stem cells and the micro-environment. Cancers (Basel) (2013) 1.01

Astrocytes reverted to a neural progenitor-like state with transforming growth factor alpha are sensitized to cancerous transformation. Stem Cells (2009) 1.01

Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer (2006) 0.98

Quantitative analysis of mitotic Olig2 cells in adult human brain and gliomas: implications for glioma histogenesis and biology. Glia (2009) 0.96

NG2-expressing cells in the nervous system: role of the proteoglycan in migration and glial-neuron interaction. J Anat (2005) 0.96

Primary brain tumors, neural stem cell, and brain tumor cancer cells: where is the link? Neuropharmacology (2010) 0.93

A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLoS One (2013) 0.93

On the origin of glioma. Ups J Med Sci (2012) 0.92

NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro Oncol (2011) 0.92

Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. Am J Pathol (2004) 0.91

Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. Cell Mol Neurobiol (2009) 0.90

Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol (2015) 0.85

p53 isoform profiling in glioblastoma and injured brain. Oncogene (2012) 0.84

Theranostic impact of NG2/CSPG4 proteoglycan in cancer. Theranostics (2015) 0.82

Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets. PLoS One (2013) 0.81

PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2. BMC Cancer (2010) 0.81

NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl-N-nitrosourea-induced gliomagenesis. Carcinogenesis (2010) 0.81

The Role of NG2 Proteoglycan in Glioma. Transl Oncol (2016) 0.79

The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma. Oncotarget (2015) 0.79

Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas. J Neurooncol (2011) 0.77

NG2 Proteoglycan Enhances Brain Tumor Progression by Promoting Beta-1 Integrin Activation in both Cis and Trans Orientations. Cancers (Basel) (2017) 0.75

Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J Neurooncol (2009) 0.75

Stem cells and the origin of gliomas: A historical reappraisal with molecular advancements. Stem Cells Cloning (2009) 0.75

Articles cited by this

A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature (1983) 6.52

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (1998) 5.30

Stem cells in the central nervous system. Science (1997) 4.77

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (1997) 3.58

Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res (1992) 3.15

Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature (1988) 2.99

Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature (1988) 2.90

A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell (1988) 2.68

Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res (1996) 2.67

Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A (1982) 2.21

Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol (1995) 2.19

Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res (1992) 2.17

Chimeric brains generated by intraventricular transplantation of fetal human brain cells into embryonic rats. Nat Biotechnol (1998) 1.95

Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol (1997) 1.89

A tripotential glial precursor cell is present in the developing spinal cord. Proc Natl Acad Sci U S A (1998) 1.87

PDGF alpha- and beta-receptors activate unique and common signal transduction pathways. EMBO J (1992) 1.85

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer (1995) 1.69

The primary structure of NG2, a novel membrane-spanning proteoglycan. J Cell Biol (1991) 1.49

Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res (1996) 1.44

Oligodendroglial progenitors labeled with the O4 antibody persist in the adult rat cerebral cortex in vivo. J Neurosci Res (1997) 1.38

Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol (1990) 1.35

Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. J Neurosci Res (1996) 1.32

Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery (1998) 1.32

Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci U S A (1996) 1.25

Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res (1985) 1.24

Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Exp Cell Res (1995) 1.22

Development and differentiation of glial precursor cells in the rat cerebellum. Glia (1993) 1.22

Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res (1991) 1.22

PDGF receptors on cells of the oligodendrocyte-type-2 astrocyte (O-2A) cell lineage. Development (1989) 1.20

The NG2 chondroitin sulfate proteoglycan: a multifunctional proteoglycan associated with immature cells. Perspect Dev Neurobiol (1996) 1.18

The origin of experimental brain tumours: a sequential study. Experientia (1976) 1.17

Mitotic activity in the primate subependymal layer and the genesis of gliomas. Nature (1968) 1.13

The role of the subependymal plate in glial tumorigenesis. Acta Neuropathol (1977) 1.12

Normal and reactive NG2+ glial cells are distinct from resting and activated microglia. J Neurosci Res (1997) 1.06

Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma. Acta Neuropathol (1984) 1.00

The expression of NG2 proteoglycan in the developing rat limb. Development (1991) 0.97

Antigenic expression by cells derived from human gliomas does not correlate with morphological classification. Neuropathol Appl Neurobiol (1988) 0.93

High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas. Oncogene (1994) 0.91

From rodent glial precursor cell to human glial neoplasia in the oligodendrocyte-type-2 astrocyte lineage. Glia (1995) 0.91

Glycolipids and myelin proteins in human oligodendrogliomas. Glycoconj J (1996) 0.87

Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas. Pediatr Neurosurg (1996) 0.83

Uniform lineage of oligodendrogliomas. Am J Pathol (1989) 0.83

Mixed oligodendroglioma and astrocytoma: fine structural and immunohistochemical studies of four cases. J Neurol Sci (1988) 0.82

p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum Pathol (1996) 0.82

Expression of oligodendrocytic mRNAs in glial tumors: changes associated with tumor grade and extent of neoplastic infiltration. Cancer Res (1997) 0.81

Expression of the genes encoding myelin basic protein and proteolipid protein in human malignant gliomas. Clin Cancer Res (1997) 0.79

Articles by these authors

Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21

Customised antenatal growth charts. Lancet (1992) 5.34

Comparison of actigraphic, polysomnographic, and subjective assessment of sleep parameters in sleep-disordered patients. Sleep Med (2001) 4.67

The Human Connectome Project: a data acquisition perspective. Neuroimage (2012) 4.64

Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. EMBO J (1997) 4.53

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol (2001) 4.06

Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain (2005) 3.99

An adjustable fetal weight standard. Ultrasound Obstet Gynecol (1995) 3.70

Antibody-mediated clearance of alphavirus infection from neurons. Science (1991) 3.70

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest (1987) 3.29

AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A (1997) 3.21

Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet (1996) 3.02

Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development (1999) 2.89

NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci (2000) 2.87

Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens (1998) 2.77

Cortical demyelination in PML and MS: Similarities and differences. Neurology (2008) 2.75

NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature (2005) 2.74

Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol (1996) 2.71

Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS (2000) 2.61

Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock (1991) 2.49

Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci (1998) 2.43

Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA (2000) 2.35

Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol (1993) 2.27

The relationship between specific tissue lesions and pain severity in persons with knee osteoarthritis. Osteoarthritis Cartilage (2006) 2.27

Plasma membrane proton ATPase Pma1p requires raft association for surface delivery in yeast. Mol Biol Cell (2001) 2.27

Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler (2003) 2.24

Expression and activity of the POU transcription factor SCIP. Science (1990) 2.23

Cardiotocography only versus cardiotocography plus PR-interval analysis in intrapartum surveillance: a randomised, multicentre trial. FECG Study Group. Lancet (2000) 2.22

Current therapy for cutaneous melanoma. J Am Acad Dermatol (1995) 2.19

Pituicytoma: a distinctive low-grade glioma of the neurohypophysis. Am J Surg Pathol (2000) 2.19

Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci (2003) 2.17

The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer (1994) 2.14

Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol (2000) 2.08

Basis of neurovirulence in Sindbis virus encephalomyelitis of mice. Lab Invest (1988) 2.05

Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci (2001) 2.04

Differential targeting of Shaker-like potassium channels to lipid rafts. J Biol Chem (2000) 2.02

Actions of saxitoxin on peripheral neuromuscular systems. J Physiol (1965) 2.00

Double minutes and homogeneously staining regions: gene amplification in mammalian cells. Annu Rev Genet (1982) 2.00

Childhood ataxia with diffuse central nervous system hypomyelination. Ann Neurol (1994) 1.98

Pancreatic acinar cells: ionic dependence of acetylcholine-induced membrane potential and resistance change. J Physiol (1975) 1.98

Pancreatic acinar cells: membrane potential and resistance change evoked by acetylcholine. J Physiol (1974) 1.96

Health services needs of children in day care centers. Am J Public Health (1978) 1.95

Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol (1994) 1.95

Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci (1999) 1.94

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst (1996) 1.93

Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol (2001) 1.92

Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. Ophthalmology (1997) 1.91

Genes involved in sister chromatid separation and segregation in the budding yeast Saccharomyces cerevisiae. Genetics (2001) 1.89

Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol (1997) 1.89

Further investigations on the mode of entry of vaccinia virus into cells. J Gen Virol (1976) 1.85

Secondary structure predictions and medium range interactions. Biochim Biophys Acta (1987) 1.84

Wallerian degeneration in the peripheral nervous system: participation of both Schwann cells and macrophages in myelin degradation. J Neurocytol (1989) 1.79

Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol (1993) 1.73

A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene (1998) 1.72

Updated gestational age specific birth weight, crown-heel length, and head circumference of Chinese newborns. Arch Dis Child Fetal Neonatal Ed (2003) 1.72

Oncocytes, oncocytosis, and oncocytic tumors. Pathol Annu (1992) 1.69

Deposits of amyloid beta protein in the central nervous system of transgenic mice. Science (1991) 1.69

Role of myelin P0 protein as a homophilic adhesion molecule. Nature (1990) 1.68

Multiple milia during treatment with acitretin for mycosis fungoides. Acta Derm Venereol (1993) 1.68

Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A (1995) 1.68

The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics (1999) 1.61

Novel genes involved in endosomal traffic in yeast revealed by suppression of a targeting-defective plasma membrane ATPase mutant. J Cell Biol (1997) 1.60

Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. Am J Hypertens (1997) 1.59

Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells. Oncogene (2006) 1.57

Controlled trial of fetal intensive care. Am J Obstet Gynecol (1976) 1.57

A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol (1997) 1.57

The effect of povidone-iodine solution applied at the conclusion of ophthalmic surgery. Am J Ophthalmol (1995) 1.56

PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J Cell Sci (1999) 1.56

FADD gene therapy for malignant gliomas in vitro and in vivo. Hum Gene Ther (1998) 1.56

P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol (2000) 1.55

Oncogenic point mutations in exon 20 of the RB1 gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype. Proc Natl Acad Sci U S A (1992) 1.54

Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology (2001) 1.53

Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. Oncogene (1996) 1.52

Pathogenesis of tissue injury in MS lesions. J Neuroimmunol (1999) 1.50

Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. Ann Intern Med (1993) 1.50

Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci U S A (1999) 1.50

Neurological deterioration in a patient with a spinal arteriovenous malformation following lumbar puncture. Case report. J Neurosurg (1990) 1.50

Genetic counselling in retinoblastoma: importance of ocular fundus examination of first degree relatives and linkage analysis. Br J Ophthalmol (1991) 1.50

Purification and analysis of in vivo-differentiated oligodendrocytes expressing the green fluorescent protein. Dev Biol (2000) 1.49

Regional modulation of neurofilament organization by myelination in normal axons. J Neurosci (1994) 1.49

NG2+ glial cells: a novel glial cell population in the adult brain. J Neuropathol Exp Neurol (1999) 1.49

IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci U S A (1984) 1.49

Video display terminals and pregnancy. A review. Br J Obstet Gynaecol (1988) 1.48

An endogenous inducer of sexual development in Aspergillus nidulans. J Gen Microbiol (1987) 1.46

Polymyxin-B hemoperfusion for acute exacerbation of idiopathic pulmonary fibrosis: serum IL-7 as a prognostic marker. Sarcoidosis Vasc Diffuse Lung Dis (2011) 1.46

Presence of the myelin-associated glycoprotein correlates with alterations in the periodicity of peripheral myelin. J Cell Biol (1982) 1.45

Presentation and management of venous aneurysms. J Vasc Surg (1997) 1.44

Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest (1996) 1.44

Axonal pathology in myelin disorders. J Neurocytol (2000) 1.43

Myelination in rat brain aggregating cell cultures. Neuroscience (1978) 1.42

An experimental study of mandibular arch widening in the dog using distraction osteogenesis. J Oral Maxillofac Surg (1998) 1.41

Regional assignment of EST sequences on human chromosome 13. Cytogenet Cell Genet (1996) 1.40